People · Operator
Named in public records as an officer, director or promoter · active 2012–2021 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Inspirna, Inc. | — | Biotechnology | Series C | $141.9M | $1.1B | 2016 |
| Tarveda Therapeutics, Inc. | — | Biotechnology | Series B | $127.4M | $141.7M | 2020 |
| Auxogyn Inc | — | Other Health Care | Series B | $73.1M | $327.3M | 2012 |
| Cirius Therapeutics, Inc. | — | Biotechnology | Series B | $49.6M | $3.3M | 2017 |
Nilesh Kumar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nilesh Kumar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Beth Seidenberg | 1 | 15 |
| Robert S Langer | 1 | 14 |
| Peter Barton Hutt | 1 | 14 |
| Jack Nielsen | 1 | 13 |
| Fred Cohen | 1 | 12 |
| Simeon George | 1 | 8 |
| Greg Garfield | 1 | 8 |
| Brian Roberts | 1 | 7 |
| ANTOINE PAPIERNIK | 1 | 6 |
| James Barrett | 1 | 6 |
| Mark Gudiksen | 1 | 5 |
| Robert Zerbe | 1 | 5 |
| Robert Beardsley | 1 | 5 |
| Dieter Weinand | 1 | 4 |
| Mark Weeks | 1 | 4 |
| Nancy Chang | 1 | 4 |
| Dennis Ausiello | 1 | 4 |
| Robert A. Beardsley | 1 | 4 |
| Mark Olesnavage | 1 | 4 |
| Omid Farokhzad | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.